ArticleGynecologic oncology reports2024
Large bowel recurrence of endometrial adenocarcinoma years after treatment: A single-institution case series and review of the literature.
Article in Gynecologic oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.
- Minimally invasive surgical treatment of recurrent endometrial carcinoma: A systematic review.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) is the most common gynecologic cancer in the United States. A majority of new cases are diagnosed as low-grade International Federation of Gynecology and Obstetrics (FIGO) Stage I, with a recurrence risk cited as less than 9 % in the first 2-3 years post-treatment. In this case series, we present three unique cases of patients with FIGO 2009 Stage I EC who all went on to present with pelvic colonic recurrences years after their initial treatment, two of the patients outside of the 5-year standard surveillance period. These presentations are described in the context of the available literature on EC colonic recurrence. A review of the literature suggests a previously cited association between endometriosis and unusual recurrence locations may not be as important of a risk factor as previously considered, as most of the cases in the series had no clinical or pathologic history of endometriosis. In addition, most of the included cases did not report a history of endometriosis and 60% of the cohort had received postoperative adjuvant radiation and still went on to experience locoregional recurrence. Further study on the associations between endometriosis, MMR status and EC recurrence, particularly for uncommon anatomic recurrence sites, are warranted to ensure appropriate and timely treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.